Mark Westberg, MD
Medical Oncology · Ankeny, IANPI 1952362394
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,082 and has fallen 98.5% since, to $16 in 2025.
Across 112 payments — averaging $13.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$165
- Seagen Inc.$124
- Pfizer$115
- Novartis$114
- E.r. Squibb & Sons, L.L.C.$95
- Agios Pharmaceuticals, Inc.$94
- plus $789 from 25 others
What the payments were for
- Food & beverage$1,42095%
- Education$755%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 29 | $165 |
| Seagen Inc. | 5 | $124 |
| Pfizer | 8 | $115 |
| Novartis | 8 | $114 |
| E.r. Squibb & Sons, L.L.C. | 7 | $95 |
| Agios Pharmaceuticals, Inc. | 1 | $94 |
| Amgen | 5 | $74 |
| Genentech USA, Inc. | 5 | $71 |
| Incyte Corporation | 4 | $52 |
| Merck | 3 | $46 |
| Sanofi | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| AstraZeneca(2 entities) | 3 | $38 |
| Bayer | 3 | $38 |
| Sun Pharmaceutical Industries Inc. | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $35 |
| Bristol Myers Squibb | 2 | $34 |
| AbbVie | 2 | $29 |
| Puma Biotechnology, Inc. | 2 | $28 |
| Tesaro, Inc. | 2 | $26 |
| Exelixis Inc. | 1 | $26 |
| Eisai Inc. | 2 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $17 |
| Dova Pharmaceuticals | 1 | $15 |
| GSK | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Rigel Pharmaceuticals, Inc. | 1 | $12 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $12 |
| Array Biopharma Inc | 1 | $11 |
How this compares
$1,495 in reported general payments places this provider in the 60th percentile of 47 medical oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 33 | $358,532 |
| ImbruvicaIbrutinib | 20 | $328,955 |
| PomalystPomalidomide | 13 | $292,240 |
| TasignaNilotinib Hcl | 13 | $244,117 |
| JakafiRuxolitinib Phosphate | 12 | $204,004 |
| XtandiEnzalutamide | 11 | $148,198 |
| XareltoRivaroxaban | 19 | $17,855 |
| EliquisApixaban | 23 | $13,273 |
| Fentanyl | 42 | $7,284 |
| Anastrozole | 264 | $2,776 |
| Hydromorphone Hcl | 24 | $1,918 |
| Letrozole | 74 | $1,257 |
| Gabapentin | 64 | $1,191 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $1,020 |
| Oxycodone Hcl | 34 | $947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $12 | $328,95520 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $95 | $292,24013 claims |
| NovartisTasigna | $114 | $244,11713 claims |
| Incyte CorporationJakafi | $52 | $204,00412 claims |
| Johnson & JohnsonXarelto | $165 | $17,85519 claims |
| PfizerEliquis | $115 | $13,27323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 47 medical oncology providers in Iowa.
Other medical oncology in Ankeny
- Zeeshan JawaAnkeny$4K
- Joshua LukenbillAnkeny$682
- Robert ShreckAnkeny$125
- Daniel BurokerAnkeny$49
- Thomas BurokerAnkeny$23
- Tara GraffClive$702K
- Jun ZhangIowa City$377K
- Mathew WehbeDes Moines$120K
- Ann StrohCedar Rapids$65K
- Praveen VikasFairfield$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.